Ask the Experts: MMR (Measles, Mumps, and Rubella)

Results (77)

In 2013, ACIP updated its recommendation for this situation (see www.cdc.gov/mmwr/pdf/rr/rr6204.pdf, pages 18–20). It is recommended that people capable of bearing children who have received 1 or 2 doses of rubella-containing vaccine and have rubella serum IgG levels that are not clearly positive should be administered 1 additional dose of MMR vaccine (maximum of 3 doses) and do not need to be retested for serologic evidence of rubella immunity. MMR should not be administered to a pregnant person.

Last reviewed: June 19, 2023

ACIP recommends that vaccinated people of childbearing age who have received one or two doses of rubella-containing vaccine and have a rubella serum IgG levels that is not clearly positive should be administered one additional dose of MMR vaccine (maximum of three doses). Repeat serologic testing for evidence of rubella immunity is not recommended. See www.cdc.gov/mmwr/pdf/rr/rr6204.pdf, pages 18–20, for more information on this issue.

MMR vaccines should not be administered to people known to be pregnant or attempting to become pregnant. Because of the theoretical risk to the fetus when the mother receives a live virus vaccine, people capable of bearing children should be counseled to avoid becoming pregnant for 28 days after receipt of MMR vaccine.

Last reviewed: June 19, 2023

MMR can be administered any time after delivery. The vaccine should be administered to a post-partum mother who is susceptible to either measles, mumps, or rubella before hospital discharge, even if the mother has received RhoGam during the hospital stay, leaves in less than 24 hours, or is breastfeeding.

Last reviewed: June 19, 2023

No. This issue has been studied extensively, including a thorough review by the independent Institute of Medicine (IOM). The IOM issued a report in 2004 that concluded there is no evidence supporting an association between MMR vaccine or thimerosal-containing vaccines and the development of autism. For more information on thimerosal and vaccines in general, visit www.cdc.gov/vaccine-safety/about/thimerosal.html.

Last reviewed: June 19, 2023

Merck no longer produces single antigen measles, mumps, and/or rubella vaccines for the U.S. market. Only combined MMR is available. You should educate parents about the lack of association between MMR and autism. You may provide parents with Immunize.org’s parent handout (developed in collaboration with the Autism Science Foundation): Evidence Shows Vaccines Unrelated to Autism, found at www.immunize.org/catg.d/p4028.pdf.

Last reviewed: June 19, 2023

Arthralgia (joint pain) and transient arthritis (joint redness or swelling) following rubella vaccination occurs only in people who were susceptible to rubella at the time of vaccination. Joint symptoms are uncommon in children and in adult biological males. About 25% of non-immune post-pubertal biological females report joint pain after receiving rubella vaccine, and about 10% to 30% report arthritis-like signs and symptoms.

When joint symptoms occur, they generally begin 1 to 3 weeks after vaccination, usually are mild and not incapacitating, last about 2 days, and rarely recur.

Last reviewed: June 19, 2023

In general, although it is not ideal, receiving extra doses of vaccine poses no medical problem. However, receiving excessive doses of tetanus toxoid (e.g., DTaP, DT, Tdap, or Td) can increase the risk of a local adverse reaction. For details see the Extra Doses of Vaccine Antigens section of the ACIP “General Best Practice Guidelines for Immunization” at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html.

Vaccination providers frequently encounter people who do not have adequate documentation of vaccinations. Providers should only accept written, dated records as evidence of vaccination. With the exception of influenza vaccine and pneumococcal polysaccharide vaccine, self-reported doses of vaccine without written documentation should not be accepted. An attempt to locate missing records should be made whenever possible by contacting previous healthcare providers, reviewing state or local immunization information systems, and searching for a personally held record.

If records cannot be located or will definitely not be available anywhere because of the patient’s circumstances, children without adequate documentation should be considered susceptible and should receive age-appropriate vaccination. Serologic testing for immunity is an alternative to vaccination for certain antigens (e.g., measles, rubella, hepatitis A, diphtheria, and tetanus).

Last reviewed: June 19, 2023

The amount of time in which a dose of vaccine must be used after reconstitution varies by vaccine and is usually outlined in the vaccine’s package insert. MMR must be used within 8 hours of reconstitution. MMRV must be used within 30 minutes; other vaccines must be used immediately. Immunize.org has a staff education piece that outlines the time allowed between reconstitution and use, as stated in the package inserts for a number of vaccines. This handout can be found at the following link: www.immunize.org/catg.d/p3040.pdf.

Last reviewed: July 26, 2023

MMRII (Merck) brand of MMR vaccine may be stored either in the refrigerator at 2°C to 8°C (36°F to 46°F) or in the freezer at -50°C to -15°C (-58°F to +5°F). Prescribing information for the Priorix (GSK) brand of MMR vaccine states that it should be stored refrigerated (at 2°C to 8°C), but not in the freezer. For both brands, the diluent should not be frozen and can be stored in the refrigerator or at room temperature.

If the MMR is combined with varicella vaccine as MMRV (ProQuad, Merck), it must be stored in the freezer at -50°C to -15°C (-58°F to +5°F).

Last reviewed: June 19, 2023

Unfortunately, serious errors in vaccine storage and handling like this occur too often. If you suspect that vaccine has been mishandled, you should store the vaccine as recommended, then contact the manufacturer or state/local health department for guidance on its use. This is particularly important for live virus vaccines like MMR and varicella.

Last reviewed: June 19, 2023

The guidance for handling after reconstitution is the same for both brands of MMR vaccine (MMRII and Priorix). It is preferable to administer MMR immediately after reconstitution. If not used immediately, the reconstituted vaccine should be store refrigerated (2°C to 8°C [36°F to 46°F]) until use. If reconstituted MMR is not used within 8 hours, it must be discarded.

Last reviewed: June 19, 2023

Only the diluent supplied with the MMR vaccine should be used to reconstitute any vaccine. A vaccine reconstituted with the incorrect diluent should be repeated.

Last reviewed: June 19, 2023

This page was updated on .

Our Affiliated Sites

For the Public: VaccineInformation.org
For Coalitions: ImmunizationCoalitions.org
65+ Flu Defense
Protect vulnerable, older adult patients from influenza.
Give2MenACWY.org
Improve protection from meningococcal serogroups ACWY.
Mass Vaccination Resources
Access guidance documents, toolkits, and helpful resources.
NAIIS
Home of the National Adult and Influenza Immunization Summit.